Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Recruiting

Phase 2

EmpagliflozinTargeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Sponsor:

University of Illinois at Chicago

Code:

NCT07175051

Conditions

Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)

Albuminuria

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Empagliflozin (oral)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-10. This information was provided to ClinicalTrials.gov by University of Illinois at Chicago on 2026-05-19.